What Do Ipamorelin and CJC-1295 Do for Women?

Ipamorelin and CJC-1295 raise growth-hormone signals in the blood. CJC-1295 holds the signal high for days to weeks and ipamorelin gives a brief pulse that fades within hours. No human trial has shown that this change improves libido, energy, skin, hair or weight in women.

How they change growth-hormone signals

CJC-1295 mimics the brain signal that tells the pituitary gland to release growth hormone. In two controlled trials in healthy adults ages 21 to 61, one injection raised average growth hormone 2 to 10 times higher for 6 or more days and raised IGF-I, a growth signal made mainly by the liver, 1.5 to 3 times higher for 9 to 11 days (CJC-1295 trial). The half-life was about 6 to 8 days, meaning half the drug cleared in that time, and with repeat doses average IGF-I stayed above starting levels for up to 28 days. No serious adverse reactions were reported in those trials.

Ipamorelin acts on a different pituitary signal and produces a much shorter effect. In a timing study in healthy men, ipamorelin cleared with a half-life of about 2 hours and triggered a single pulse of growth hormone that peaked at about 0.67 hours and then fell to very low levels (ipamorelin timing study).

What this means for libido, energy and hormones

Those human trials measured hormone levels in blood. They did not measure sexual desire, daily energy, sleep quality, skin, hair or body fat, and none of the trials focused on women. The ipamorelin timing study enrolled only men.

Selectivity testing in conscious pigs found ipamorelin did not raise the stress hormones ACTH or cortisol, even at doses more than 200 times the dose needed for growth-hormone release, and did not change reproductive signals FSH and LH, prolactin, or thyroid signal TSH (selectivity study). Those results show a focused signal in that model. They do not show that your estrogen, testosterone, desire or energy will change.

How to decide your next step

If you are 30 to 55 and your main concerns are low drive or low energy, these findings leave you without a proven benefit to expect. You may see higher growth-hormone numbers on labs, but the trials give you no reason to expect higher desire or steadier daytime energy.

One medical practice describes its typical candidates as adults 30 to 65 who notice lighter sleep, shifts in body composition and slower recovery despite steady diet, training and sleep habits. That practice starts low and adjusts over 8 to 12 weeks and lists brief flushing, tingly hands and vivid dreams as common early effects (provider guide). That description reflects one clinic's experience, not controlled trial results.

If low libido or low energy brought you here, take the HOD quiz to check which HOD plan fits your symptoms and history.